Australian (ASX) Healthcare Sector Analysis

Sector Valuation and Performance

Has the Australian Healthcare Sector valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE
Tue, 30 Nov 2021	AU$239.5b	AU$56.1b	AU$4.7b	30.4x
Thu, 28 Oct 2021	AU$234.5b	AU$55.2b	AU$4.5b	30.2x
Sat, 25 Sep 2021	AU$241.4b	AU$55.6b	AU$4.6b	30.8x
Mon, 23 Aug 2021	AU$238.6b	AU$55.1b	AU$4.5b	29.6x
Sat, 10 Jul 2021	AU$226.8b	AU$55.1b	AU$4.5b	30.7x
Fri, 02 Apr 2021	AU$208.7b	AU$52.5b	AU$3.8b	23.1x
Mon, 04 Jan 2021	AU$211.4b	AU$50.7b	AU$3.1b	31.9x
Thu, 08 Oct 2020	AU$210.2b	AU$50.3b	AU$2.8b	30.5x
Wed, 01 Jul 2020	AU$204.0b	AU$49.6b	AU$2.5b	27.4x
Sat, 04 Apr 2020	AU$192.9b	AU$51.5b	AU$3.5b	20.6x
Tue, 07 Jan 2020	AU$197.2b	AU$49.6b	AU$3.7b	21.4x
Mon, 30 Sep 2019	AU$175.7b	AU$49.4b	AU$3.8b	20.6x
Thu, 04 Jul 2019	AU$164.3b	AU$47.7b	AU$3.6b	22.3x
Sun, 07 Apr 2019	AU$146.2b	AU$46.5b	AU$3.5b	21.4x
Wed, 09 Jan 2019	AU$136.4b	AU$45.3b	AU$3.4b	22.9x

PE Ratio

20.4x

Fri, 07 Dec 2018

Current Industry PE: Investors are relatively neutral on the industry at the moment, considering it's trading close to its 3-year average PE ratio of 25.7x. It appears they believe that earnings will grow in-line with historical growth rates.

Past Earnings Growth: The earnings for companies in the Healthcare industry have grown 12% per year over the last three years, and revenues for these companies have grown 8.4% per year. This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Australian Healthcare sector?


Healthtech	1.54%
Healthcare Services	0.14%
Medical Equipment	-0.66%
Life Sciences	-1.93%
Biotech	-3.36%
Pharma	-3.78%

Industry PE: Investors are most optimistic about the Healthtech industry, which is trading close to its 3-year average PE ratio of 123x. However analysts expect its future annual earnings growth (36%) to be largely in line with prior year's earnings growth, so the market might believe analysts are underestimating its future growth since investors are willing to pay a bigger premium today. Meanwhile, investors are most pessimistic about the Medical Equipment industry, which is trading below its 3-year average of 32.2x.

Forecasted Growth: Analysts are most optimistic on the Pharma industry, expecting annual earnings growth of 67% over the next 5 years. This is better than it's past earnings growth rate of 5.6% per year. Meanwhile, the Healthcare Services industry is expected to see its earnings growth to stay flat over the next few years.

Company	7D	1Y	Valuation
SHL Sonic Healthcare	3.3%+AU$647.5m	28.5%	n/a
PME Pro Medicus	4.1%+AU$255.7m	108.6%	n/a
IDT IDT Australia	48.8%+AU$48.0m	229.7%	n/a
ANN Ansell	1.0%+AU$39.5m	-15.8%	n/a
BIT Biotron	84.0%+AU$29.5m	10.8%	n/a

Company

Valuation

SHL Sonic Healthcare

3.3%+AU$647.5m

28.5%

n/a

PME Pro Medicus

4.1%+AU$255.7m

108.6%

n/a

IDT IDT Australia

48.8%+AU$48.0m

229.7%

n/a

ANN Ansell

1.0%+AU$39.5m

-15.8%

n/a

BIT Biotron

84.0%+AU$29.5m

10.8%

n/a

Seqirus Announces U.S. FDA Approval for Multi-Dose Vial Presentation of First-Ever Adjuvanted, Cell-Based Pandemic Influenza Vaccine

CSL Limited announced that the U.S. Food and Drug Administration (FDA) has granted supplemental approval of a multi-dose vial (MDV) presentation of AUDENZ™ (Influenza A(H5N1) Monovalent Vaccine, Adjuvanted), the first-ever adjuvanted, cell-based influenza vaccine designed to help protect individuals six months of age and older against influenza A(H5N1) in the event of a pandemic. The FDA approval of the MDV presentation of AUDENZ™, which was originally approved by the FDA in 2020 in a single dose, prefilled syringe (PFS) presentation, marks an important milestone in Seqirus' pandemic preparedness efforts in partnership with Biomedical Advanced Research and Development Authority (BARDA), a component of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Under the terms of the public-private partnership, established in 2009, Seqirus would position itself to deliver 150 million influenza vaccine doses to the U.S. government to support an influenza pandemic response within six months. Seqirus' Adjuvanted, Cell-Based Technology: AUDENZ™ combines Seqirus' proprietary MF59® adjuvant technology with its cell-based manufacturing platform. Cell-based manufacturing, an alternative to traditional egg-based manufacturing, avoids egg-adapted changes, one source of strain mismatch between the vaccine and circulating influenza virus. Influenza vaccines using the MF59® adjuvant are designed to enhance and broaden the body's immune response by creating broad, cross-reactive antibodies. This adjuvant is an important part of pandemic preparedness planning as it reduces the amount of antigen required to produce an immune response, increasing the number of doses of vaccine developed, so that a large number of people can be vaccinated as quickly as possible.

Australian (ASX) Healthcare Sector Analysis

Sector Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

RAC

Insider recently sold AU$4.4m worth of stock

ACW

Actinogen Medical Announces Enrolment Reach in the XanaMIA Part A Trial of 105 Participants

MYX

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Therapeutic Goods Administration Approval of NEXTSTELLIS® Oral Contraceptive

BIT

Here's Why We're Not Too Worried About Biotron's (ASX:BIT) Cash Burn Situation

CSL

Seqirus Announces U.S. FDA Approval for Multi-Dose Vial Presentation of First-Ever Adjuvanted, Cell-Based Pandemic Influenza Vaccine

ANN

Here's Why I Think Ansell (ASX:ANN) Is An Interesting Stock

IDT

Here's Why Shareholders Will Not Be Complaining About IDT Australia Limited's (ASX:IDT) CEO Pay Packet

CUV

This Is The Reason Why We Think Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Might Be Underpaid

COH

Independent Non-Executive Director recently bought AU$56k worth of stock

AT1

Atomo Diagnostics Limited (ASX:AT1) Shares Could Be 50% Below Their Intrinsic Value Estimate

PME

Is Now The Time To Put Pro Medicus (ASX:PME) On Your Watchlist?

SHL

We Like Sonic Healthcare's (ASX:SHL) Returns And Here's How They're Trending

PNV

PolyNovo Limited's (ASX:PNV) CEO Compensation Looks Acceptable To Us And Here's Why

TLX

Independent Non-Executive Chairman exercised options to buy AU$6.0m worth of stock.

RHC

Full year 2021 earnings released: EPS AU$1.93 (vs AU$1.31 in FY 2020)

RHY

Rhythm Biosciences Limited Completes Recruitment for Clinical Trial (Study 7)